From: Mobile health, exercise and metabolic risk: a randomized controlled trial
Characteristic | Intervention (n =75) | Active Control (n =74) |
---|---|---|
Demographics | ||
Age (years) | 55.7 (10.1) | 57.8 (8.7) |
Sex (female) | 55 (73.3%) | 56 (75.7%) |
Race (Caucasian)† | 74 (100%) | 73 (100%) |
Smoking status: | ||
Current | 3 (4.0%) | 1 (1.4%) |
Former | 31 (41.3%) | 29 (39.2%) |
History of Type 2 Diabetes | 3 (4.0%) | 4 (5.4%) |
Antihypertensive Therapy | 27 (36.0%) | 33 (44.6%) |
Monotherapy | 16 (59.3%) | 21 (63.6%) |
Combination Therapy | 11 (40.7%) | 12 (36.3%) |
Angiotensin Converting | ||
Enzyme Inhibitors | 10 (37.0%) | 20 (60.6%) |
Angiotensin Receptor Blockers | 6 (22.2%) | 10 (30.3%) |
Calcium Channel Blockers | 4 (14.8%) | 1 (3.0%) |
Diuretics | 17 (63.0%) | 15 (45.4%) |
Alpha Receptor Blockers | 1 (3.7%) | 0 (0%) |
Average frequency of physical activity (in last 7 days), median (IQR)‡ | 2.5 (3.5) | 3.0 (4.0) |
pVO2max | 30.5 (6.8) | 31.2 (6.3) |